Precision Medicine Quarterly

Broad Institute Launches $1K Sample-to-Report Clinical Whole-Genome Sequencing Service

2023-04-12T14:47:20-05:00April 12th, 2023|

As clinical whole-genome sequencing (WGS) is becoming more of a routine diagnostic test for certain patients with genetic disorders, the Broad Institute has launched a new end-to-end WGS and variant interpretation service in partnership with genome analysis company Fabric Genomics. Priced at $1,000 per sample, the new test promises to be competitive with other [...]

Agilent, PathAI Forge Deal on Algorithm-Supported Assay Development

2023-04-12T14:29:16-05:00April 12th, 2023|

Agilent Technologies and digital pathology firm PathAI are partnering to develop assays and distribute PathAI's software and algorithms to anatomic pathology laboratories, they announced on Wednesday. Santa Clara, California-based Agilent and Boston-based PathAI said the multiyear deal covers the development of assays, including companion diagnostics and digital pathology tests. "This partnership brings together our [...]

New Lung Cancer Evolution, Treatment Response Patterns Emerge From TRACERx Study

2023-04-12T14:26:06-05:00April 12th, 2023|

New results from the UK's Tracking Cancer Evolution through Therapy (TRACERx) study are providing a close look at the evolution of non-small cell lung cancer including intratumor heterogeneity (ITH), treatment-related tumor adaptations, tumor features influencing disease progression and metastasis, immune interactions, and other tumor evolutionary clues related to clinical outcomes. The prospective, multicenter TRACERx [...]

Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug

2023-04-12T14:21:18-05:00April 12th, 2023|

Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to include companion diagnostic development for the pharma firm's investigational tyrosine kinase inhibitor repotrectinib. Repotrectinib is an orally administered tyrosine kinase inhibitor that is being evaluated in an ongoing registrational Phase I/II trial called TRIDENT-1 for patients with TKI-naive [...]

Illumina, Henry Ford Health Partner on Genomic Testing for Cardiovascular Patients

2023-04-12T14:18:14-05:00April 12th, 2023|

Illumina and Henry Ford Health said on Tuesday that they have launched a partnership to study the impact of whole-genome sequencing in cardiovascular disease.Under the terms of the deal, Henry Ford's centers for precision medicine and genomic medicine in Detroit will conduct implementation and clinical studies to investigate the use of next-generation sequencing tests, including [...]

Go to Top